COMP <GO>
GH vs DGX // EV/EBITDA & P/E VALUATION
Guardant Health Inc. (NASDAQ) VS. Quest Diagnostics Incorporated (NYSE) • 15-METRIC TALLY: GH 4
— DGX 9
■ METRIC PARITY
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
valuation
—
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
valuation
16.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. DGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | DGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.50% | 33.20% | +31.30 | GH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 10.30% | -27.70 | DGX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 16.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 4.88% | -5.82 | DGX | /fcf-yield <GO> |
| Operating Margin | -44.50% | 14.10% | -58.60 | DGX | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 9.00% | -51.40 | DGX | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 11.80% | +21.10 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.27% | -1.27 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 4.01 | +1.43 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | DGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.0 | 69.4 | -7.40 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.01 | -0.14 | DGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 26.1x | -7.10 | GH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $27.83B | -$2.96B | DGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | DGX REV | GH GROSS % | DGX GROSS % | GH FCF | DGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $11.04B | 64.5% | 33.2% | -$233.1M | $1.36B |
| FY 2024 | $739.0M | $9.87B | 60.8% | 32.9% | -$274.9M | $909.0M |
| FY 2023 | $563.9M | $9.25B | — | — | -$350.4M | $855.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
DGX // BETA 1.01